PetVivo Holdings Inc
PETV
$1.280 -7.51%
Exchange: OTC | Sector: Healthcare | Industry: Medical Devices
Q4 2024
Published: Jul 9, 2024

Earnings Highlights

  • Revenue of $0.05M down 61.6% year-over-year
  • EPS of $-0.19 increased by 13.6% from previous year
  • Gross margin of 466.9%
  • Net income of -2.65M
  • "N/A" - N/A

PetVivo Holdings Inc (PETV) QQ4 2024 Earnings Analysis: Revenue Contraction, Large Net Loss, and Liquidity Tightness in a Niche Veterinary Medical Devices Market

Executive Summary

PetVivo Holdings reported a Q4 2024 financials snapshot that underscores significant top-line contraction and a continued heavy cost base, resulting in a sizable net loss and negative cash flow from operations. Revenue for QQ4 2024 stood at 48,266 USD, while gross profit appeared to be 225,356 USD with an unusual negative cost of revenue entry (leading to an implied gross margin of ~4.67%). The company posted an operating loss of -2.65 million USD and a net loss of -2.65 million USD, with EBITDA of -3.15 million USD. EPS was -0.19, and YoY/QoQ comparisons point to deteriorating revenue (-61.57% YoY; -91.90% QoQ) alongside a mixed margin picture (gross margin ~4.7%; operating margin ~-54.9%; net margin ~-54.9%). Free cash flow was deeply negative at approximately -1.55 million USD, while operating cash flow was -1.52 million USD. Financing activities provided 1.56 million USD, yielding a modest net cash increase of about 7k USD; cash at period-end was 87 thousand USD. The balance sheet shows limited liquidity with current assets of ~1.04 million USD and current liabilities of ~1.41 million USD, yielding a current ratio of 0.74 and a quick ratio of 0.46. Long-term debt totaled ~1.02 million USD, total debt ~1.37 million USD, and stockholders’ equity ~0.686 million USD, with retained earnings deeply negative (~-82.8 million USD). Stock-based compensation was substantial at ~0.64 million USD, and R&D and SG&A expenses remained high, totaling over 2.9 million USD in operating expenses. Management commentary is not provided in the supplied transcript data; consequently, there are no direct quotes to anchor a narrative from the earnings call. The four-quarter and dated-cash-flow dynamics suggest the business remains in an early-stage phase requiring external financing to sustain operations. Investors should weigh the potential upside from Spryng adoption and pipeline devices against the substantial near-term liquidity and profitability risks. Given the absence of formal forward guidance in the available data, the near-term trajectory hinges on monetization of the Spryng platform, licensing opportunities, and the company’s ability to secure additional capital.

Key Performance Indicators

Revenue

48.27K
QoQ: -91.90% | YoY:-61.57%

Gross Profit

225.36K
4.67% margin
QoQ: -45.41% | YoY:852.96%

Operating Income

-2.65M
QoQ: -24.19% | YoY:-13.78%

Net Income

-2.65M
QoQ: -51.48% | YoY:-13.81%

EPS

-0.19
QoQ: -58.33% | YoY:13.64%

Revenue Trend

Margin Analysis

Key Insights

  • QQ4 2024 Revenue: 48,266 USD; YoY change: -61.57%; QoQ change: -91.90%
  • Gross Profit: 225,356 USD; Gross Margin: 4.67% (anomalous given negative cost of revenue entry of -177,090 USD; implies unusual accounting items in the period)
  • EBITDA: -3,145,832 USD; EBITDA Margin: -65.18%
  • Operating Income: -2,649,796 USD; Operating Margin: -54.90%
  • Net Income: -2,650,717 USD; Net Margin: -54.92%

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.30 -0.09 +516.4% View
Q3 2025 0.58 -0.09 -2.1% View
Q2 2025 0.20 -0.11 -3.2% View
Q1 2025 0.12 -0.11 +5.6% View
Q4 2024 0.05 -0.19 -61.6% View